Next Article in Journal
Locally-Delivered T-Cell-Derived Cellular Vehicles Efficiently Track and Deliver Adenovirus Delta24-RGD to Infiltrating Glioma
Next Article in Special Issue
Options and Obstacles for Designing a Universal Influenza Vaccine
Previous Article in Journal
Paramyxovirus Glycoprotein Incorporation, Assembly and Budding: A Three Way Dance for Infectious Particle Production
Previous Article in Special Issue
Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases
Open AccessReview

Virus-Vectored Influenza Virus Vaccines

Department of Infectious Diseases, University of Georgia, 111 Carlton St., Athens, GA 30602, USA
Author to whom correspondence should be addressed.
Viruses 2014, 6(8), 3055-3079;
Received: 12 June 2014 / Revised: 28 July 2014 / Accepted: 29 July 2014 / Published: 7 August 2014
(This article belongs to the Special Issue Virus-based Vaccines)
Despite the availability of an inactivated vaccine that has been licensed for >50 years, the influenza virus continues to cause morbidity and mortality worldwide. Constant evolution of circulating influenza virus strains and the emergence of new strains diminishes the effectiveness of annual vaccines that rely on a match with circulating influenza strains. Thus, there is a continued need for new, efficacious vaccines conferring cross-clade protection to avoid the need for biannual reformulation of seasonal influenza vaccines. Recombinant virus-vectored vaccines are an appealing alternative to classical inactivated vaccines because virus vectors enable native expression of influenza antigens, even from virulent influenza viruses, while expressed in the context of the vector that can improve immunogenicity. In addition, a vectored vaccine often enables delivery of the vaccine to sites of inductive immunity such as the respiratory tract enabling protection from influenza virus infection. Moreover, the ability to readily manipulate virus vectors to produce novel influenza vaccines may provide the quickest path toward a universal vaccine protecting against all influenza viruses. This review will discuss experimental virus-vectored vaccines for use in humans, comparing them to licensed vaccines and the hurdles faced for licensure of these next-generation influenza virus vaccines. View Full-Text
Keywords: influenza virus; vaccine; recombinant vaccine; virus vector; universal vaccine influenza virus; vaccine; recombinant vaccine; virus vector; universal vaccine
MDPI and ACS Style

Tripp, R.A.; Tompkins, S.M. Virus-Vectored Influenza Virus Vaccines. Viruses 2014, 6, 3055-3079.

AMA Style

Tripp RA, Tompkins SM. Virus-Vectored Influenza Virus Vaccines. Viruses. 2014; 6(8):3055-3079.

Chicago/Turabian Style

Tripp, Ralph A.; Tompkins, S. M. 2014. "Virus-Vectored Influenza Virus Vaccines" Viruses 6, no. 8: 3055-3079.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Search more from Scilit
Back to TopTop